Younger patients with non-small cell lung cancer in good general condition survive notably longer with the new drug than with the comparator therapy. The added benefit is non-quantifiable in older patients, say reviewers.
Younger patients with non-small cell lung cancer in good general condition survive notably longer with the new drug than with the comparator therapy. The added benefit is non-quantifiable in older patients, say reviewers.